慢加急性肝衰竭的定义、病理生理学基础和临床管理

刘海霞; 朱跃科; 孟庆华

doi:10.3969/j.issn.1001-5256.2016.09.010

慢加急性肝衰竭的定义、病理生理学基础和临床管理

DOI: 10.3969/j.issn.1001-5256.2016.09.010

首都医科大学附属北京佑安医院肝病重症医学科

详细信息

中图分类号: R575.3
计量
- 文章访问数: 2639
- HTML全文浏览量: 17
- PDF下载量: 515
- 被引次数: 0
出版历程
- 出版日期: 2016-09-20

Definition,pathophysiology,and clinical management of acute-on-chronic liver failure

Department of Critical Care Medicine of Liver Disease, Beijing YouAn Hospital, Capital Medical University

摘要

摘要: 慢加急性肝衰竭(ACLF)是原有慢性肝病在急性打击下发生肝功能的急剧恶化,病死率极高。由于东西方国家的肝病基础和急性损伤的潜在致病因素不同,一直以来诊断存在很多争议,但ACLF的病情有逆转可能的本质相同,早期诊断及合理治疗可能改善预后。从易患因素、诱发因素、损伤后反应、器官功能衰竭角度了解了ACLF的病理生理学基础,从而阐述合理管理,改善患者生存率。
- 肝功能衰竭 /
- 病理生理学 /
- 疾病管理
Abstract: Acute- on- chronic liver failure( ACLF) is defined as rapid deterioration of liver function under acute attack in patients with chronic liver disease and is associated with an extremely high mortality. Since the basis of liver disease and potential pathogenic factors for acute injury are different in Chinese and Western medicine,the diagnosis remains controversial. However,there is a consensus on the fact that the condition of ACLF can be reversed,and early diagnosis and reasonable treatment can improve prognosis. This article introduces the pathophysiology of ACLF from the aspects of risk factors,predisposing factors,response after injury,and organ failure and elaborates on the reasonable management measures to improve patients' survival rate.
- liver failure /
- pathophysiology /
- disease management

HTML全文

参考文献(15)

[1]OHNISHI H,SUGIHARA J,MORIWAKI H,et al.Acute-on-chronic liver failure[J].Ryoikibetsu Shokogun Shirizu,1995,(7):217-219.

[2]SARIN SK,KUMAR A,ALMEIDA JA,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)[J].Hepatol Int,2009,3(1):269-282.

[3]JALAN R,GINES P,OLSON JC,et al.Acute-on chronic liver failure[J].J Hepatol,2012,57(6):1336-1348.

[4]Liver Failure and Artificial Liver Group,Chinese Society of Infectious Disease,CMA;Severe Liver Disease and Artificial Liver Group Chinese Society of Hepatology;CMA.Guidelines for diagnosis and treatment of liver failure(2012 version)[J].J Pract Hepatol,2013,16(3):210-216.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].实用肝脏病杂志,2013,16(3):210-216.

[5]BAJAJ JS,O’LEARY JG,REDDY KR,et al.Second infections independently increase mortality in hospitalized patients with cirrhosis:the North American consortium for the study of end-stage liver disease(NACSELD)experience[J].Hepatology,2012,56(6):2328-2335.

[6]JALAN R,STADLBAUERV,SEN S,et al.Role of predisposition,injury,response and organ failure in the prognosis of patients with acute-on-chronic liver failure:a prospective cohort study[J].Crit Care,2012,16(6):r227.

[7]MOREAU R,JALAN R,GINES P,et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterology,2013,144(7):1426-1437.

[8]LI H,XIA Q,ZENG B,et al.Submassive hepatic necrosis distinguishes HBV-associated acute-on chronic liver failure from cirrhotic patients with acute decompensation[J].J Hepatol,2015,63(1):50-59.

[9]GUSTOT T,FELLEITER P,PICKKERS P,et al.Impact of infection on the prognosis of critically ill cirrhotic patients:results from a large worldwide study[J].Liver Int,2014,34(10):1496-503.

[10]ARABI YM,DARA SI,MEMISH Z,et al.Antimicrobial therapeutic determinants of outcomes fromseptic shock among patients with cirrhosis[J].Hepatology,2012,56(6):2305-2315.

[11]GUSTOT T,MAILLART E,BOCCI M,et al.Invasive aspergillosis in patients with severe alcoholic hepatitis[J].J Hepatol,2014,60(2):267-274.

[12]BAJAJ JS,O’LEARY JG,REDDY KR,et al.Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J].Hepatology,2014,60(1):250-256.

[13]MARTIN-LLAHI M,GUEVARA M,TORRE A,et al.Prognostic importance of the cause of renal failure in patients with cirrhosis[J].Gastroenterology,2011,140(2):488-496.

[14]BOYER TD,SANYAL AJ,WONG F,et al.Initial report of a large,randomized,double blind,placebo-controlled,phase 3 trial of terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome(HRS-1):the REVERSE study[J].Hepatology,2014,60:255A.

[15]ROMERO-GMEZ M,MONTAGNESE S,JALAN R.Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-onchronicliver failure[J].J Hepatol,2015,62(2):437-447.

施引文献

资源附件(0)

访问统计